Cargando…
mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Academy of Allergy, Asthma & Immunology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526431/ https://www.ncbi.nlm.nih.gov/pubmed/34678498 http://dx.doi.org/10.1016/j.jaip.2021.09.051 |
| _version_ | 1784585864689483776 |
|---|---|
| author | Koo, Grace Anvari, Sara Friedman, Debra L. Zarnegar-Lumley, Sara Szafron, Vibha Kahwash, Basil M. Onasch, K. Michelle Hall, Laura Phillips, Elizabeth J. Stone, Cosby A. |
| author_facet | Koo, Grace Anvari, Sara Friedman, Debra L. Zarnegar-Lumley, Sara Szafron, Vibha Kahwash, Basil M. Onasch, K. Michelle Hall, Laura Phillips, Elizabeth J. Stone, Cosby A. |
| author_sort | Koo, Grace |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8526431 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Academy of Allergy, Asthma & Immunology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85264312021-10-20 mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase Koo, Grace Anvari, Sara Friedman, Debra L. Zarnegar-Lumley, Sara Szafron, Vibha Kahwash, Basil M. Onasch, K. Michelle Hall, Laura Phillips, Elizabeth J. Stone, Cosby A. J Allergy Clin Immunol Pract Clinical Communications American Academy of Allergy, Asthma & Immunology 2022-01 2021-10-20 /pmc/articles/PMC8526431/ /pubmed/34678498 http://dx.doi.org/10.1016/j.jaip.2021.09.051 Text en © 2021 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Clinical Communications Koo, Grace Anvari, Sara Friedman, Debra L. Zarnegar-Lumley, Sara Szafron, Vibha Kahwash, Basil M. Onasch, K. Michelle Hall, Laura Phillips, Elizabeth J. Stone, Cosby A. mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase |
| title | mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase |
| title_full | mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase |
| title_fullStr | mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase |
| title_full_unstemmed | mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase |
| title_short | mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase |
| title_sort | mrna covid-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase |
| topic | Clinical Communications |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526431/ https://www.ncbi.nlm.nih.gov/pubmed/34678498 http://dx.doi.org/10.1016/j.jaip.2021.09.051 |
| work_keys_str_mv | AT koograce mrnacovid19vaccinesafetyinpatientswithpreviousimmediatehypersensitivitytopegaspargase AT anvarisara mrnacovid19vaccinesafetyinpatientswithpreviousimmediatehypersensitivitytopegaspargase AT friedmandebral mrnacovid19vaccinesafetyinpatientswithpreviousimmediatehypersensitivitytopegaspargase AT zarnegarlumleysara mrnacovid19vaccinesafetyinpatientswithpreviousimmediatehypersensitivitytopegaspargase AT szafronvibha mrnacovid19vaccinesafetyinpatientswithpreviousimmediatehypersensitivitytopegaspargase AT kahwashbasilm mrnacovid19vaccinesafetyinpatientswithpreviousimmediatehypersensitivitytopegaspargase AT onaschkmichelle mrnacovid19vaccinesafetyinpatientswithpreviousimmediatehypersensitivitytopegaspargase AT halllaura mrnacovid19vaccinesafetyinpatientswithpreviousimmediatehypersensitivitytopegaspargase AT phillipselizabethj mrnacovid19vaccinesafetyinpatientswithpreviousimmediatehypersensitivitytopegaspargase AT stonecosbya mrnacovid19vaccinesafetyinpatientswithpreviousimmediatehypersensitivitytopegaspargase |